Novo Nordisk selects ‘local presence’ for Asia-Pacific distribution

By Maggie Lynch

- Last updated on GMT

(Image: Getty/ Local Images)
(Image: Getty/ Local Images)

Related tags Asia pacific Asia API compound distribution agreement Pharmaceutical companies Novo Nordisk Pharmatech Novo nordisk

Novo Nordisk Pharmatech selected DKSH to distribute its pharmaceutical grade compounds to the company’s growing customer base in the Asia-Pacific region.

DKSH, an ingredients and chemicals distributor, was chosen for Novo Nordisk’s pharmaceutical grade compounds (quats) due to its logistical infrastructure and experience in the region.

Steve Profit, global sales and marketing director at Novo Nordisk Pharmatech, told us, “South East Asia is a fast-growing market with massive expansion happening within existing customers’ sites plus new business ventures in exciting new high growth regions.”

“To ensure that our customers worldwide get the best partner for key supplies possible, we wanted a partner with not only a local presence and excellent service but one that had a shared vision towards business ethics and product expertise to deliver excellence to our customers.”

DKSH is located within the region with an “omni-channel approach” ​for a “one-stop regional solution”​ for its clients. Profit explained that Asia-Pacific is the third largest pharmaceutical market in the world. He added that, in the region, “pharma sales will grow 8.4% by 2021.”

The quats include benzalkonium chloride, cetrimonium bromide, and cetrimide.

In a statement Tanja Schaffer, vice president, global pharmaceutical industry, DKSH, said that the quats it will be distributing are a “perfect fit”​ for its active pharmaceutical ingredients portfolio.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more